Key facts
- Notable investors include Creative Destruction Lab, National Institutes of Health, Endless Frontier Labs, K5 Global, Silicon Catalyst — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Phinomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Phinomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phinomics
Developer of genomic technologies designed to create circular deoxyribonucleic acid systems to address challenging unmet needs in healthcare. The company's technology focuses on extrachromosomal circular DNA to build advanced approaches combining AI-driven platforms, single-cell analysis, and bioinformatics to uncover molecular markers for targeted treatment therapies, clinical diagnostics, and drug discovery, enabling clinicians to prevent, diagnose, and treat disorders driven by changes in DNA.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2020
- Employees
- 8
- Website
- phinomics.com/
- Ownership
- Privately Held (backing)
Phinomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phinomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phinomics in its N-PORT filings yet. We sweep new filings monthly.